Journal article

Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory Fc gamma R functions

S Siberil, C de Romeuf, N Bihoreau, N Fernandez, JL Meterreau, A Regenman, E Nony, C Gaucher, A Glacet, S Jorieux, P Klein, MP Hogarth, WH Fridman, D Bourel, R Beliard, JL Teillaud

CLINICAL IMMUNOLOGY | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2006

Abstract

The substitution of plasmatic anti-RhD polyclonal antibodies by a monoclonal antibody (mAb) for preventing the hemolytic disease of the newborn (HDN) is an important issue due to supply and safety concerns. Since it has been suggested that FcgammaR are involved in the prevention of HDN, the in vitro functional properties of two anti-RhD mAbs differing through their glycosylation profiles were compared using FcgammaR-based assays to select a candidate mAb. T125(YB2/0), a low fucosylated antibody, bound strongly to both activating FcgammaRIII and inhibitory FcgammaRII, as opposed to its highly fucosylated counterpart. It also exerted a strong ADCC against RhD+ RBCs and a potent FcgammaRIIB-med..

View full abstract

University of Melbourne Researchers